"Trafuril"* is the trade name of a cream containing 5 per cent. by weight of tetrahydrofurfuryl nicotinic acid ester in a water-miscible base. The cutaneous reaction which follows the local application of this substance has been described by Strehler (1949) . It is characterized by the appearance, within 10 to 30 minutes, of erythema usually accompanied by superficial oedema.
Nassim and Banner (1952) made the interesting observation that this response was absent in patients with active rheumatoid arthritis. In less acute cases, a mild erythema only was produced. In those with minimal evidence of activity or in remission, a normal or subnormal response was the rule. The diminished skin reaction in a proportion of patients with rheumatoid disease was subsequently confirmed by Oka (1953) , Vaillancourt (1954) , and Bartfeld and Hartung (1954) . In these reports no mention was made of whether the patients were being treated with aspirin at the time of testing. Leifer and Batterman (1955) sequent reaction was similar to that seen in healthy controls. On the basis of these observations it was decided to study in more detail the effect of aspirin on the reaction to "Trafuril" in normal subjects and in patients with rheumatoid arthritis.
Material and Methods
Tests were made on healthy hospital staff and on patients in hospital suffering from "definite" rheumatoid arthritis according to the diagnostic criteria proposed by the American Arthritis and Rheumatism Foundation (Ropes, Bennett, Cobb, Jacox, and Jessar, 1956) . They were on a basic regimen consisting of rest in bed, splinting of affected joints, and physiotherapy. Initially all were receiving aspirin in doses of 60-80 gr. daily.
The ester was used in the form of the 5 per cent. "Trafuril" cream, or as a 5 per cent. solution in 0-15 M sodium chloride.
Tests were made by applying approximately 120 mg. "Trafuril" cream uniformly to an area one inch in diameter on the volar surface of the forearm, or by applying the solution to a similar area of skin.
Reactions were graded as follows: 0-No erythema 1-Erythema without oedema 2-Erythema and oedema Aspirin was given by mouth in the form of tablets which produced 5 gr. calcium aspirin when dissolved in water. Solutions for intradermal injection were prepared by dissolving calcium aspirin in 0-15 M sodium chloride. The pH was adjusted to between 7 and 8 by the addition of 0-1 M sodium hydroxide.
Aspirin and free salicylate in the blood were estimated by the method described by Smith (1951) . 137 
Results
Characteristics of the Reaction.-Application of "Trafuril" cream to the skin of healthy subjects resulted in the appearance of a punctate erythema within 5 to 10 minutes. The erythema rapidly became confluent and covered an area corresponding exactly to the site of application (Fig. 1) . Superficial oedema then developed (Fig. 2) , and in most subjects the area became surrounded by a flare. The reaction reached its maximum intensity in half an hour and faded gradually thereafter. The erythema persisted for a further 4 to 5 hours. Strehler (1949) "Trafuril" was applied 1 hour later. A proportion of subjects in these tests showed erythema arising at the site of application of the "Trafuril" from 2 to 3 hours later.
Ten normal subjects were therefore given 10 gr. calcium aspirin by mouth and a standard application of the ester was made 1 hour later. The reactions were read after half an hour and thereafter hourly for the following 5 hours. A control group of ten subjects was similarly tested. The results are illustrated in Fig. 3 (opposite) . The greatest difference between the groups was observed half an hour after the application of the ester. At this time the subjects who had been given the aspirin showed pallor or faint blueness at the site of application (Fig. 4, overleaf) .
Erythema developed in this area after 2 to 3 hours (Fig. 5, overleaf Local Effect of Aspirin on Reaction to "Trafuril".-0-1 ml. of a solution of calcium aspirin containing 4 mg./ml. was injected intradermally into the forearm. "Trafuril" cream was applied to the area 1 hour later. When the reaction was read after a further half hour, an area of pallor 20 mm. in diameter was apparent surrounding the site of injection (Fig. 6 ). This area became erythematous after a further 24 hours and was then no longer distinguishable from the surrounding erythema. Injection of 0 1 ml. of 0 15 M sodium chloride had no such effect. An injection containing one-tenth of the dose of aspirin produced a rather smaller area of modified response (Fig. 6, overleaf) .
Effect of Variations in Dose of Aspirin.-In normal subjects a single dose of 10 gr. calcium aspirin by mouth was always sufficient to cause suppression of the immediate reaction to "Trafuril". An attempt was made to determine the lowest dose of aspirin sufficient to achieve this effect and to correlate this dose with the levels of aspirin and free salicylate in the blood. Thirteen normal subjects were given doses of calcium aspirin by group.bmj.com on June 24, 2017 -Published by http://ard.bmj.com/ Downloaded from mouth varying from 2-5 to 10 gr. and were tested at varying times later. The results showed that suppression of the early phase of the reaction could be complete even when aspirin or free salicylate could not be detected in the blood and that this effect persisted for 24 hours or longer.
Discussion
The response to "Trafuril" applied to the skin of normal subjects has been described. Patients with rheumatoid arthritis who were not receiving aspirin showed a similar reaction. Furthermore, both patients and controls showed a characteristic modification of the response when aspirin was given by mouth. There can be little doubt that the abnormal response in patients with rheumatoid arthritis previously reported was due to the ingestion of aspirin.
Consideration of the effect of aspirin on the characteristics of the reaction suggests that there are two phases: an early phase of erythema, oedema, and surrounding flare, fading in I to 21 hours, and a later phase of erythema alone. Aspirin appears to exert its effect on the early phase of the reaction. It may be noted that oedema was never a feature of the late phase of the reaction.
Modification of the early phase around the site of an intradermal injection of aspirin is evidence in favour of the idea that the drug has a direct local action. The continued suppressive effect of aspirin for as long as 24 hours after a small dose by mouth, when it can no longer be detected in the blood, suggests fixation by the tissues.
Further work is in progress to determine whether aspirin is effective in modifying erythema or oedema induced by other agents, and whether other drugs claimed to have an anti-inflammatory action can modify the reaction to the nicotinic acid ester in a similar way.
The mode of action of this ester in producing erythema and oedema on direct application to the skin is unknown. The evidence available at present (Strehler, 1949; Oka, 1953) does not suggest that the reaction is due directly to release of histamine or that aspirin is anti-histaminic. However, it seems reasonable to suppose that the action of aspirin demonstrated in these experiments may bear a relationship to its therapeutic effect in the treatment of such conditions as rheumatic fever and rheumatoid arthritis.
Summary
(1) The characteristics of the reaction induced in normal skin by the application of the tetrahydrofurfuryl ester of nicotinic acid have been described.
(2) The reaction in patients with rheumatoid arthritis who are not receiving aspirin differs in no way from the normal.
(3) The early phase of the reaction is significantly modified in both normal and rheumatoid subjects by the administration of aspirin by mouth and by the intradermal injection of soluble aspirin before application of the ester.
(4) It is suggested that the action of aspirin demonstrated in these experiments may be related to its therapeutic effect in the treatment of diseases such as rheumatic fever and rheumatoid arthritis.
During the period when this work was done, the Rheumatic Unit was in receipt of grants from the Nuffield Foundation, the Medical Research Council, and Boots Pure Drug Company Limited.
